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Abstract
Maintenance of thyroid function during pregnancy is critical
for both maternal and fetal health and development; therefore, knowledge regarding the relationship between thyroid
hormones and pregnancy is essential. The American Thyroid
Association task force has developed clinical guidelines on
the diagnosis and treatment of thyroid disease during pregnancy. Gestational thyroid diseases are divided into two
classifications, hypothyroidism and hyperthyroidism, which
are further divided into more specific classifications based
on clinical presentation. Differentiation, diagnosis, and monitoring of thyroid diseases throughout pregnancy require
assessing symptoms, as well as obtaining levels of thyroidstimulating hormone (TSH) and free thyroxine (FT 4) concentration by a simple serum test. Treatment goals are based on
trimester-specific normal ranges of these hormone levels.
Uncontrolled hypothyroidism and hyperthyroidism during
pregnancy can lead to adverse pregnancy complications and
have negative effects on fetal development. However, debate
still exists as to the benefit of thyroid hormone level screening in all pregnant patients versus only those with higher
risk.
Introduction
Pregnancy has a significant impact on the thyroid gland and
thyroid function. Knowledge regarding the relationship between thyroid hormones and pregnancy is advancing at a
rapid pace.1 Many studies are now focusing on the potential
impact of hypothyroidism or hyperthyroidism, as well as
treatment outcomes on maternal and fetal health. It is important to recognize that until between 10 and 12 weeks gestation, the fetus is entirely dependent upon placental transfer
of maternal thyroid hormone. Although maintenance of
maternal thyroid hormone levels is critical throughout the
entire pregnancy, avoidance of suboptimal levels is of great
importance during this time.2 By the end of the first trimester, the fetal thyroid begins producing thyroid hormones on
its own, but remains dependent on the mother for ingestion
of adequate amounts of iodine, an essential component in the
production of thyroid hormones. During pregnancy, the maternal thyroid gland increases in size by 10 to 40 percent.
Along with a SO percent increase in maternal daily iodine
requirement, production of thyroxine (T 4) and triiodothyronine (T3) also increases by SO percent during this time. Serum
thyroid-stimulating hormone (TSH) levels fall during the first
trimester of a normal pregnancy as a physiological response
to the stimulating effect of human chorionic gonadotropin
(hCG) on the TSH receptor. Normal TSH levels during pregnancy range from 0.03 mIU/mL to 2.5 mIU/mL.1
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veloped clinical guidelines for the diagnosis and treatment of
thyroid disease during pregnancy. Hypothyroidism during
gestation is defined as the presence of an elevated serum
TSH concentration. Hypothyroidism is prevalent in 2 percent
of pregnancies and can be further classified as either subclinical (SCH) or overt hypothyroidism (OH), dependent
upon measurement of serum free thyroxine (FT 4) concentration. Hyperthyroidism is characterized by an overactive thyroid gland and defined by elevated FT 4, as a result of increased serum concentrations of T4and T3, and suppressed
or undetectable serum TSH. 1 Thyroid hormone fluctuations
associated with hypothyroidism and hyperthyroidism have
been shown to impact both maternal and fetal health and
development.

Diagnosis and Complications of Hyperthyroidism During
Pregnancy
Hyperthyroidism is less common during pregnancy than hypothyroidism. It is estimated that the prevalence falls in the
range of 0.1 percent to 0.4 percent, with 85 percent of cases
attributed to Graves' disease.3 Graves' disease is most common in women during the reproductive years and can be
associated with infertility. Most pregnant women with hyperthyroidism are diagnosed with Graves' disease prior to
conception. In the first trimester, a diagnosis of Graves' disease is based on very low serum TSH (<0.lmIU/L) and elevated FT 4, which must be differentiated from gestational hyperthyroidism.1 Gestational hyperthyroidism is characterized by low serum TSH and elevated FT 4 during the first half
of pregnancy, as well as the absence of serum markers of
thyroid autoimmunity. In patients with Graves' disease, TSH
receptor antibodies (TRAb) will be present and physical findings may include a goiter or thyroid-associated orbitopathy.
Obstetric complications, such as increased risk of stillbirth,
miscarriage and premature birth, are similar to the complications seen with hypothyroidism.3 Patients with uncontrolled
hyperthyroidism during pregnancy may experience congestive heart failure, thyroid storm triggered by preeclampsia or
maternal TRAb may cross the placenta and stimulate the fetal thyroid. Stimulation of the fetal thyroid can lead to fetal
tachycardia, fetal growth retardation, cardiac failure, development of a fetal goiter and, rarely, neonatal hyperthyroidism.
Treatment and Monitoring of Hyperthyroidism
For patients with a diagnosis of Graves' disease, the safest
time to conceive is while euthyroid. 1 It is strongly suggested
that uncontrolled patients planning on becoming pregnant
use adequate contraception until they become euthyroid. A
hyperthyroid patient may be treated with ablative therapy or
antithyroid drugs (ATD) prior to conception, but after con-
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ception the preferred treatment is ATD. The main antithyroid
drugs used are propylthiouracil (PTU) and methimazole
(MMl).3 During the first trimester, the current ATD of choice
is PTU because more teratogenic effects have been associated with MMJ.1 Women on MMI prior to conception should
be switched to treatment with PTU. After the first trimester,
patients may consider switching to MMI because there have
been reports of hepatotoxicity with prolonged PTU treatment.1-3 Both PTU and MMI cross the placental barrier; for
this reason, the lowest dose of ATD that maintains FT 4 levels
at or moderately above the normal reference values should
be used.1 Levels of FT4 and TSH should be monitored every
two to six weeks during pregnancy with a primary goal of
keeping FT 4 levels controlled. If maternal FT 4 levels are not
under control, fetal heart rate, growth and thyroid size may
be evaluated as needed using ultrasound. 4 Lactating mothers
should be treated with MMI doses up to 30mg/day given in
divided doses immediately following each feeding. PTU is
typically avoided during lactation due the hepatotoxicity
risks. 1
Antithyroid drugs are not indicated for the treatment of
gestational hyperthyroidism, because FT 4 levels return to
normal by 14 to 18 weeks gestation.1 Gestational hyperthyroidism may cause nausea and vomiting in the form of
hyperemesis gravidum. Management should include supportive therapy for symptoms and hospitalization if required.

Diagnosis and Complications of Hypothyroidism During
Pregnancy
Hypothyroidism can be difficult to diagnose during pregnancy.s.6 Typical symptoms of hypothyroidism such as
weight gain, muscle cramps, constipation, fatigue and dry
skin are common symptoms of pregnancy itself. For this reason, a diagnosis of hypothyroidism is confirmed by an increase in serum TSH. 6 Hypothyroidism during pregnancy is
differentiated into overt and subclinical types. The estimated
prevalence of each type during pregnancy is 0.2 to 0.3 percent and 2 to 2.5 percent, respectively.7 Overt hypothyroidism (OH) during pregnancy is defined as an elevated TSH
level of greater than 2.5 mlU /L in conjunction with a decreased FT4 concentration or a TSH level above 10mlU/L
regardless of FT4 levels. 1.s Subclinical hypothyroidism (SCH)
is defined as a TSH level within the range of 2.SmIU/L and
10mIU/L with a normal FT4 level. OH is symptomatic
whereas SCH may be symptomatic or asymptomatic.s
When left untreated, OH has been firmly associated with adverse pregnancy complications and negative effects on fetal
brain development.1.9 Depending on when during the pregnancy untreated OH is present, it can lead to infertility, increased risk of preeclampsia, premature birth, low birth
weight, miscarriage, increased admission to neonatal intensive care and perinatal morbidity and mortality_l. 4,1 Maternal
OH in all trimesters has been associated with the development of fetal neurological deficits, but during the third trimester the fetal thyroid gland is able to provide some thyroid
hormone to the fetus lessening the severity of fetal brain
damage occurring during the last trimester.6.10 Untreated
SCH is associated with similar adverse pregnancy outcomes,
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but whether or not it has negative effects on infertility or
causes neurocognitive deficits in the developing fetus remains controversiaJ.1.lO

Treatment and Monitoring of Hypothyroidism
The goal of treatment for both OH and SCH is to normalize
serum TSH to the following trimester-specific ranges: first
trimester 0.1 mIU/L to 2.5 mIU/L; second trimester 0.2 mIU/
L to 3.0 mIU/L; and third trimester 0.3 to 3.0 mIU/L .1 It is
important to note these ranges are lower than the 0.4 mIU/L
to 4.0 mIU/L target range for non-pregnant women.a The
American Thyroid Association recommends using levothyroxine (LT 4) thyroid preparations rather than TJ or dessicated preparations. 1 Up to SO to 80 percent of women receiving exogenous levothyroxine prior to pregnancy will require
a dosage increase during pregnancy.a For patients planning a
pregnancy and receiving exogenous levothyroxine for a diagnosis of hypothyroidism, a levothyroxine dosage adjustment
should be made as soon as pregnancy is suspected or immediately after a missed menstrual cycle. The American Thyroid
Association recommends an approximate 25 to 30 percent
increase in dose for euthyroid newly pregnant women receiving levothyroxine. 1 This can be accomplished using a two
tablet dosage increase based on a prospective, randomized
trial by Yassa et al. The study demonstrated a reduced risk of
maternal hypothyroidism during the first trimester when
patients had their total weekly T4 dose increased by two tablets.11 For example, a woman on seven tablets per week
would increase her dose to nine tablets per week.1 Maternal
TSH levels should be monitored every four weeks during the
first 20 weeks of pregnancy for patients receiving levothyroxine and patients with untreated SCH because further dosage adjustments are often required to keep TSH in range.
Maternal TSH should be checked again at least once between
26 and 32 weeks gestation. Thyroxine (T1J requirements will
likely increase as the pregnancy progresses.6 Pharmacists can
help maximize intestinal absorption of the hormone by counseling patients to take levothyroxine on an empty stomach
with a glass of water, either one hour before or two hours
after a meal and four hours apart from products containing
iron such as prenatal vitamins.6.12
Postpartum, TSH levels and T4 requirements should return to
their pre-pregnancy state allowing patients to resume their
pre-pregnancy dosing schedules. 1 TSH should be checked at
six weeks postpartum.

Screening for Thyroid Function
There is much discussion as to the benefit of monitoring thyroid hormone levels during pregnancy, and it has been five
years since the American Association of Clinical Endocrinologists recommended thyroid function screening in all women
during the first trimester of pregnancy.13 The most recent
guidelines set forth by the Endocrine Society recommend
screening in high-risk women as opposed to routine screenings in pregnancy. 14 High-risk women should be screened for
thyroid function during and/or before pregnancy (Table 1).
Despite these criteria, a single-center cohort study that
measured TSH, free T4 and free T3 in 1,560 consecutive preg-
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nant women during their first visit to the gynecologist at a
median of nine weeks gestation, discovered that thyroid
function testing of only the high-risk women would miss
about one-third of pregnant women with hypothyroidism
(Table 1).15 Thus, it is recommended from the results of this
particular trial that all pregnant women receive thyroid function tests.
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antithyroid drug therapy, specifically propylthiouracil and
methimazole. Although there is much debate as to whether
or not thyroid function tests are necessary in pregnant
women, studies show that testing is cost-effective and should
be recommended to ensure the health of both mother and
fetus.
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Table 1. Characteristics of Women at High Risk for Thyroid Disease1 4
Past history of thyroid disease

Goiter

Thyroid lobectomy

TRAbs

Family history of thyroid disease

Type I diabetes

Symptoms or clinical signs of hyperthyroidism

Symptoms or clinical signs of hypothyroidism

Autoimmune disorders

Infertility

Previous therapeutic head and neck irradiation

History of miscarriage and preterm delivery
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